Tepylute is a drug owned by Shorla Pharma Ltd. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 16, 2041. Details of Tepylute's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11975013 | Stable formulations comprising thiotepa |
Aug, 2041
(16 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Tepylute is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tepylute's family patents as well as insights into ongoing legal events on those patents.
Tepylute's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tepylute's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 16, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tepylute Generic API suppliers:
Thiotepa is the generic name for the brand Tepylute. 11 different companies have already filed for the generic of Tepylute, with Meitheal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tepylute's generic
About Tepylute
Tepylute is a drug owned by Shorla Pharma Ltd. Tepylute uses Thiotepa as an active ingredient. Tepylute was launched by Shorla in 2024.
Approval Date:
Tepylute was approved by FDA for market use on 25 June, 2024.
Active Ingredient:
Tepylute uses Thiotepa as the active ingredient. Check out other Drugs and Companies using Thiotepa ingredient
Dosage:
Tepylute is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 15MG/1.5ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |